Tavoosian Ali, Reis Leonardo Oliveira, Aluru Pavan, Khajavi Alireza, Aghamir Seyed Mohammad Kazem
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
UroScience and Department of Surgery (Urology), School of Medical Sciences, University of Campinas, Unicamp, Pontifical Catholic University of Campinas, PUC-Campinas, Campinas, São Paulo, Brazil.
Ann Med Surg (Lond). 2022 Jul 9;80:104137. doi: 10.1016/j.amsu.2022.104137. eCollection 2022 Aug.
To date, no study evaluates the effect of atherosclerosis risk level on the efficacy of BPH drug therapies. Therefore, the present study aimed to assess the effect of atherosclerosis risk levels on the effectiveness of Tamsulosin and Tadalafil in LUTS treatment.
The present study was a randomized clinical trial that assessed men with LUTS symptoms (at least six months). The inclusion criteria were being older than 50 years, international prostate symptom score (IPSS) ≥ 13, and maximum urinary flow rate (Qmax) between 4 and 15 ml/s. Framingham Risk Score was used to measure atherosclerosis risk. The patients were classified into four groups, including group 1: Patients with low risk and treated with Tamsulosin (0.4 mg/day), group 2: Patients with low risk and treated with Tadalafil (5 mg/day), group 3: Patients with high risk and treated with Tamsulosin (0.4 mg/day), group 4: Patients with high risk and treated with Tadalafil (5 mg/day).
The study included 44 and 38 patients receiving Tamsulosin and Tadalafil, respectively. The means (SD) of the baseline age for the Tamsulosin and Tadalafil groups were equal to 60.6 (6.8) and 58.8 (6.7), respectively (p-value = 0.213). The models revealed no impact of the atherosclerosis risk level on the drugs' effects (p-values = 0.378, 0.975, 0.743 for IPSS, QMAX, and VOID, respectively).
The present study's findings could not show the impact of atherosclerosis risk levels on the efficiency of Tamsolusin and Tadalafil in men with LUTS.
迄今为止，尚无研究评估动脉粥样硬化风险水平对良性前列腺增生症（BPH）药物治疗疗效的影响。因此，本研究旨在评估动脉粥样硬化风险水平对坦索罗辛和他达拉非治疗下尿路症状（LUTS）有效性的影响。
本研究为一项随机临床试验，评估有LUTS症状（至少6个月）的男性。纳入标准为年龄大于50岁、国际前列腺症状评分（IPSS）≥13且最大尿流率（Qmax）在4至15毫升/秒之间。采用弗明汉姆风险评分来衡量动脉粥样硬化风险。患者被分为四组，包括：第1组：低风险患者，接受坦索罗辛治疗（0.4毫克/天）；第2组：低风险患者，接受他达拉非治疗（5毫克/天）；第3组：高风险患者，接受坦索罗辛治疗（0.4毫克/天）；第4组：高风险患者，接受他达拉非治疗（5毫克/天）。
该研究分别纳入了44例和38例接受坦索罗辛和他达拉非治疗的患者。坦索罗辛组和他达拉非组的基线年龄均值（标准差）分别为60.6（6.8）和58.8（6.7）（p值 = 0.213）。模型显示动脉粥样硬化风险水平对药物疗效无影响（IPSS、QMAX和排尿量的p值分别为0.378、0.975、0.743）。
本研究结果未能显示动脉粥样硬化风险水平对LUTS男性患者使用坦索罗辛和他达拉非疗效的影响。
Zotero 插件